Events

Cardiovascular disease and chronic inflammation are closely interconnected, while advances in genomics, multiomics, biomarker discovery, and pharmacogenomics are creating new opportunities for more precise prevention, diagnosis, and treatment. The COST Actions CardioPharmaGENET (CA24165) and INFLAMomx (CA24166) are joining forces to explore the role of precision medicine in addressing the complex relationship between cardiovascular disease and inflammation. The…

As part of her activities as Chair of the CardioPharmaGENET, Dr. Adna Ašić participated in the COST Academy training “Understanding EU decision-making processes: How to advocate your interest”.The training provided an in-depth and highly interactive overview of European Union decision-making and legislative processes, with a particular focus on how research communities can effectively engage with…

CardioPharmaGENET was presented at the 13th Panhellenic Congress of the Hellenic Society of Basic and Clinical Pharmacology, held in Patras, Greece (15-17 May 2026), and organized by Prof. Evangelia Papadimitriou, Chair of the Hellenic Society of Basic and Clinical Pharmacology (HSBCP).An oral presentation titled “Introduction to COST Action CA24125 CardioPharmaGENET: Exploration of the roads of…

Our WG5 Vice Leader and Deputy Science Communication Coordinator, Amra Džuho, participated in the COST Academy workshops Science for Policy and International Scientific Networking, held in Brussels, Belgium.The workshops brought together representatives of COST Actions and international research networks to strengthen participants’ capacity to connect scientific evidence with policymaking, foster stakeholder engagement, and enhance the…

CardioPharmaGENET was presented at the 14th ISABS & Mayo Clinic Conference: Advances in Application of Artificial Intelligence in Precision Medicine, held in Dubrovnik, Croatia. The conference brought together leading experts from academia, healthcare, and industry to discuss the latest developments in precision medicine, artificial intelligence, and genomics.During the conference, the Chair of the CardioPharmaGENET, Dr….

Advancing precision cardiovascular medicine requires strong integration between scientific research, clinical innovation, and evidence-based policymaking. Within this context, members of the CardioPharmaGENET (CA24165) community continue to contribute actively not only to scientific development, but also to shaping European health policy frameworks. A productive meeting took place in Brussels between Jonathan Gomez-Raja, Management Committee representative for…

Productive discussions were held in Brussels within the framework of CardioPharmaGENET (CA24165), reflecting the Action’s continued commitment to strengthening interdisciplinary collaboration at the interface of cardiovascular challenges and translational precision medicine. The activities in Brussels, attended by SCC dr. Theodora Katsila, combined scientific exchange and capacity-building perspectives, highlighting the importance of effective communication and coordinated…

Members of the CardioPharmaGENET COST Action gathered from 11–13 May 2026 in Darmstadt for the Annual Meeting hosted at GSI Helmholtzzentrum für Schwerionenforschung. The three-day meeting brought together researchers, clinicians, industry representatives, patient stakeholders, policymakers, and Young Research Investigators from across Europe to discuss recent developments, strengthen collaborations, and define future directions in cardiovascular pharmacogenomics and precision medicine. The Annual…

Yvan Devaux, Co-Chair of the CardioPharmaGENET Action, delivered a lecture on precision medicine within the brain–heart axis at the FOKUS Patient Future Days in Stockholm. His presentation highlighted the importance of integrating molecular, clinical, and computational approaches to better understand the complex interactions between neurological and cardiovascular systems.This contribution reflects the ongoing commitment of CardioPharmaGENET…